Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2022-04-27 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于所属企业药品通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a pharmaceutical product passing a regulatory evaluation (仿制药一致性评价) by the National Medical Products Administration (国家药品监督管理局). It details the drug's basic information, regulatory approval, market impact, and risk warnings. The document is short (1217 characters) and serves as a formal public disclosure of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or management analysis. It is not a report publication announcement since it contains substantive content about the approval and its implications. The document fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about product approval and market impact without fitting into more specific categories like earnings, management changes, or capital updates.
2022-04-27 Chinese
哈药集团股份有限公司九届十三次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It includes the supervisory board's review and approval of the company's 2022 first quarter report, stock option cancellations, stock repurchases, and stock option exercise conditions. The document is relatively short (2229 characters) and primarily contains the supervisory board's opinions and approvals rather than the full financial report itself. It also references other announcements published on the Shanghai Stock Exchange website for detailed information. This indicates that the document is an announcement of supervisory board resolutions and approvals related to financial and stock incentive matters, not the full quarterly report or financial statements. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not contain full financial data or detailed reports.
2022-04-27 Chinese
哈药集团股份有限公司独立董事关于公司九届二十四次董事会相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Harbin Pharmaceutical Group Co., Ltd. regarding several board matters, including the cancellation and repurchase of stock options and restricted stocks under the 2021 stock incentive plan, the exercise and lifting of restrictions on stock options and restricted stocks, and the appointment of a senior management member. The document references compliance with company law, securities law, and stock incentive management rules, and discusses board procedures and approvals. It is not a full financial report, earnings release, or audit report. It is a formal opinion related to board decisions and management appointments, which fits the category of Board/Management Information (MANG). The document length is short (1985 characters), and it contains substantive content about board decisions rather than just an announcement or certification. Therefore, the appropriate classification is MANG with high confidence.
2022-04-27 Chinese
哈药集团股份有限公司关于公司副总经理辞职的公告
Board/Management Information Classification · 100% confidence The document is a short announcement regarding the resignation of the company's vice general manager. It includes no financial data, no report or presentation, and no regulatory or legal proceedings. It is an announcement about a change in senior management. Therefore, it fits the category of Board/Management Information (MANG). The document length is very short (347 characters), consistent with a brief management change announcement.
2022-04-27 Chinese
哈药集团股份有限公司关于2021年股票期权与限制性股票激励计划首次授予第一个行权期行权条件及第一个解除限售期解除限售条件成就的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement from 哈药集团股份有限公司 regarding the 2021 stock option and restricted stock incentive plan. It discusses the first exercise period and lifting of restrictions for stock options and restricted stocks, including the number of shares, exercise prices, approval processes, performance conditions, and legal opinions. The content focuses on the company's stock incentive plan execution and related approvals, which is typical of announcements related to share-based compensation and capital changes. It is not a full financial report, audit report, or earnings release. It is also not a simple announcement of a report publication but a substantive disclosure about stock option exercises and restricted stock unlocking. This fits best under the category of Share Issue/Capital Change (SHA), as it involves issuance of shares to incentive plan participants and changes in capital structure due to stock option exercises and restricted stock releases.
2022-04-27 Chinese
哈药集团股份有限公司九届二十四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.) detailing decisions made at the 24th meeting of the 9th board of directors. It includes approval of the 2022 first quarter report, appointment of a new vice general manager and securities affairs representative, and decisions related to stock option and restricted stock incentive plans. The document references the 2022 first quarter report and other announcements published separately on the Shanghai Stock Exchange website, indicating that the actual financial report is not included here. The document is relatively short (2194 characters) and serves as an official announcement of board decisions rather than a full financial report or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG) as it primarily announces board resolutions and management appointments.
2022-04-27 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.